Clinical trial
Three Combinations Of Docetaxel And Irinotecan For Recurrent Or Metastatic Non…
NCT00139711 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00139711 |
|---|---|
| Title | Three Combinations Of Docetaxel And Irinotecan For Recurrent Or Metastatic Non Small Cell Lung Cancer |
| Official title | A Multicenter Randomized Phase II Study Evaluating The Activity And Tolerability Of Three Different Combinations Of Docetaxel (Taxotere) And Irinotecan (Campto) As Second Line Therapy For Recurrent Or Metastatic Non Small Cell Lung Cancer (NSCLS) |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Non-Small-Cell Lung |
| Intervention type | Drug |
| Interventions | Irinotecan, Docetaxel |
| Enrollment | 138 |
| Start date | Mar 1, 2003 |
| Completion | Jun 1, 2006 |
| First posted | Aug 31, 2005 |
| Last update posted | Apr 1, 2008 |
| Countries | Italy |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: